• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, November 21, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Immediate Treatment Benefits High-Risk Mycobacterium avium Lung Infections Over Watchful Waiting

by
November 20, 2026
in Health
Reading Time: 6 mins read
0
Immediate Treatment Benefits High-Risk Mycobacterium avium Lung Infections Over Watchful Waiting

Immediate Treatment Benefits High-Risk Mycobacterium avium Lung Infections Over Watchful Waiting

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A retrospective propensity score matched cohort analysis revealed that initiating immediate antibiotic therapy for Mycobacterium avium complex pulmonary disease significantly improved survival strictly among patients presenting with moderate-to-severe illness, while providing no overall survival benefit across the broader patient population. Published in the journal Infectious Diseases and Therapy, the investigation addressed a long-standing therapeutic dilemma regarding whether newly diagnosed individuals should immediately undertake prolonged multi-drug regimens or enter structured observation. Researchers discovered that while immediate antibiotic administration accelerated sputum culture conversion, it concurrently caused a marked increase in adverse drug reactions. Crucially, the observed survival gains from upfront intervention were concentrated exclusively among patients stratified into higher clinical risk tiers using the validated BACES scoring system.

Mycobacterium avium complex, which encompasses Mycobacterium avium and Mycobacterium intracellulare, represents the leading cause of non-tuberculous mycobacterial pulmonary disease globally. The pathogen induces chronic respiratory infections presenting across a diverse spectrum of severity, from slowly progressing nodular bronchiectatic changes to aggressive, tissue-destroying fibrocavitary disease. Clinical management of this infection remains particularly challenging because standard therapeutic guidelines from the American Thoracic Society and the Infectious Diseases Society of America emphasize multi-drug regimens centered on macrolides, typically combining azithromycin or clarithromycin with ethambutol and rifampicin. These demanding antimicrobial regimens require extended treatment durations and carry significant risks of patient toxicity, including severe gastrointestinal disturbances, hepatotoxicity, and sensory impairments such as ototoxicity and vision loss.

Because clinical progression is notoriously variable, pulmonologists have frequently debated the necessity of immediate antimicrobial initiation versus watchful waiting. While certain untreated individuals experience spontaneous microbiological clearance or remain radiologically and clinically stable for years, delayed intervention in aggressive phenotypes can result in irreversible parenchymal damage and heightened treatment complexity. To delineate clear criteria for therapeutic timing, a research team led by investigators at Seoul National University Bundang Hospital in South Korea conducted an extensive evaluation of treatment-naïve adult patients diagnosed with Mycobacterium avium complex pulmonary disease between May 2003 and October 2021. All enrolled participants fulfilled standard consensus diagnostic criteria requiring clinical symptoms, characteristic radiographic abnormalities, and definitive microbiological identification from sputum cultures, bronchoscopy specimens, or lung biopsies.

From an initial cohort of 1,276 screened individuals, the investigators excluded 684 patients who lacked complete baseline data, including missing erythrocyte sedimentation rate measurements, unavailable body mass index records, or absent chest computed tomography scans within one year of diagnosis. The remaining 592 treatment-naïve individuals were classified into two primary management pathways based on real-world clinical timelines. Immediate treatment was formally defined as starting systemic antibiotic therapy within two months, or sixty days, of microbiological confirmation, a window reflecting the practical duration needed to complete species identification and drug susceptibility testing. Conversely, the watchful waiting group comprised individuals who either remained completely untreated or delayed therapy initiation beyond the two-month threshold following progressive disease manifestation.

To control for substantial baseline prognostic discrepancies between aggressively treated and monitored individuals, researchers employed one-to-one propensity score matching using a nearest-neighbor caliper algorithm. Covariates incorporated into the matching algorithm included patient age, sex, body mass index, erythrocyte sedimentation rate, diagnosis via bronchoscopy, and the presence of significant cavitary lesions measuring at least two centimeters on computed tomography. This statistical procedure yielded 102 well-balanced matched pairs, representing 204 patients with closely matched baseline demographic and clinical profiles. Within this matched population, the median age was approximately 67 years, females represented 47.1 percent of the immediate group and 45.1 percent of the watchful waiting group, and cavitary lesions larger than two centimeters were present in roughly 30 percent of patients in both arms.

Microbiological profiles across the matched cohorts showed a comparable distribution of species, with Mycobacterium avium accounting for 46.1 percent of cases in the immediate group and 56.9 percent in the watchful waiting group, followed by Mycobacterium intracellulare. Comorbid conditions such as prior tuberculosis, chronic obstructive pulmonary disease, interstitial lung disease, and malignancy demonstrated balanced prevalence between groups. Baseline sputum smear positivity, which initially appeared significantly higher among patients selected for immediate intervention in the unmatched cohort, achieved statistical balance following propensity score adjustment at 23.5 percent versus 15.7 percent. Baseline clinical symptoms were similarly distributed, dominated by chronic cough in 34.3 percent of patients, productive sputum in 29.4 percent, and hemoptysis in 17.6 percent.

Analysis of microbiological trajectories revealed that immediate antibiotic treatment achieved significantly faster sputum culture conversion than watchful waiting. Patients receiving upfront therapy attained culture conversion at a hazard ratio of 3.07 with a 95 percent confidence interval spanning 1.68 to 5.61. The overall culture conversion rate reached 45.1 percent in the immediate treatment arm compared with 26.5 percent among observed controls. Furthermore, the median duration required to attain culture conversion from initial diagnosis was substantially shorter among immediate recipients at 3.27 months versus 9.23 months in the watchful waiting group. Follow-up sputum surveillance was conducted at comparable intervals between both cohorts, ensuring that observed differences in microbiological clearance were not artifacts of disparate testing frequency.

However, the microbiological advantage of early therapy was accompanied by substantial clinical toxicity. Adverse events were documented in 64.7 percent of patients receiving immediate antibiotic treatment, compared with 41.2 percent among those managed initially with watchful waiting who subsequently received medications. Gastrointestinal discomfort occurred in 38.2 percent of the immediate arm compared to 22.5 percent of the observation group, representing a statistically significant escalation. Visual disturbances, encompassing both subjective symptoms and objective complications such as ethambutol-related optic neuritis, were observed five times more frequently in the immediate therapy arm at 14.7 percent versus 2.9 percent. Other complications, including clinical hepatotoxicity, dermatological reactions, and dizziness, occurred at comparable frequencies between groups.

When examining primary survival endpoints across the entire matched cohort, immediate treatment failed to demonstrate a measurable reduction in mortality. The stratified hazard ratio for all-cause mortality between the immediate treatment and watchful waiting groups was 0.92 with a 95 percent confidence interval of 0.53 to 1.61, reflecting no statistically significant difference in overall survival. Similarly, respiratory or infection-related mortality exhibited no statistically significant divergence across the broad cohort, yielding a hazard ratio of 0.47 with a 95 percent confidence interval ranging from 0.19 to 1.14. Parallel evaluations conducted across the entire unmatched cohort of 592 individuals corroborated this absence of baseline survival divergence under generalized immediate antibiotic implementation.

A critical divergence emerged when investigators evaluated disease severity using the validated BACES scoring system. Incorporating five distinct clinical metrics—body mass index below 18.5 kilograms per square meter, age 65 years or older, cavitary lesions on chest computed tomography, elevated erythrocyte sedimentation rate, and male sex—the BACES score stratifies patients into mild, moderate, and severe categories. In the exploratory subgroup of patients presenting with moderate-to-severe disease defined by a BACES score of two or higher, immediate therapy conferred a pronounced survival advantage. Upfront intervention in this group reduced all-cause mortality with a hazard ratio of 0.53 and decreased respiratory mortality with a hazard ratio of 0.35, with survival curves separating markedly between two and five years post-diagnosis.

In contrast, other exploratory subgroup stratifications did not demonstrate significant survival benefits from immediate antibiotic administration. Extending the definition of observation to a six-month threshold eliminated survival differences after matching, while continuing to show increased adverse event frequencies in early treatment recipients. Likewise, isolating patients based solely on isolated smear positivity or the presence of large cavitary lesions failed to show statistically significant mortality improvements with upfront therapy. Notably, among patients managed under watchful waiting, 53.9 percent ultimately required treatment initiation after a median observation period of 4.89 months, whereas 46.1 percent remained clinically stable without any antimicrobial intervention across a median follow-up exceeding five years.

The study authors highlighted several methodological limitations inherent to their single-center retrospective design, including the exclusion of patients lacking baseline erythrocyte sedimentation rate measurements and the inability to completely eliminate unmeasured confounding such as patient frailty. Furthermore, documented adverse events relied upon clinical chart reviews rather than systematic prospective monitoring, which might have underestimated transient toxicities. Despite these constraints, the investigators concluded that generalized immediate antibiotic administration should not be universally mandated for all individuals diagnosed with Mycobacterium avium complex pulmonary disease. Instead, a risk-stratified strategy guided by multi-parameter clinical severity tools like the BACES score enables clinicians to deliver timely life-prolonging therapy to high-risk patients while safely sparing milder cases unnecessary drug toxicity.

Subject of Research: Clinical outcomes of immediate treatment versus watchful waiting in Mycobacterium avium complex pulmonary disease

Article Title: Immediate Treatment Versus Watchful Waiting in Mycobacterium avium Complex Pulmonary Disease: A Propensity Score Matched Analysis

Article References: Hwang, A., Hwang, H., Joo, D.-H., Lee, Y. J., Kwon, B. S., Kim, Y. W., Park, J. S., Kwak, N., Yim, J.-J., Kim, H.-J., & Lee, J. H. (2026). Immediate Treatment Versus Watchful Waiting in Mycobacterium avium Complex Pulmonary Disease: A Propensity Score Matched Analysis. Infectious Diseases and Therapy, 15(11), 3057-3071. https://doi.org/10.1007/s40121-026-01433-1

Image Credits: AI Generated

DOI: 10.1007/s40121-026-01433-1

Keywords: Mycobacterium avium complex, pulmonary disease, nontuberculous mycobacteria, watchful waiting, immediate treatment, antibiotic therapy, propensity score matching, culture conversion, adverse events, BACES score, respiratory mortality, all-cause mortality, macrolide therapy, retrospective cohort, disease severity, sputum conversion, bronchiectasis, chest computed tomography, infectious disease

News Source: Ophelia Keating. (November 20, 2026). Immediate Treatment Benefits High-Risk Mycobacterium avium Lung Infections Over Watchful Waiting. Scienmag.

Tags: adverse eventsall-cause mortalityantibiotic therapyBACES scorebronchiectasischest computed tomographyculture conversionDisease severityimmediate treatmentinfectious diseasemacrolide therapyMycobacterium avium complexnontuberculous mycobacteriapropensity score matchingpulmonary diseaserespiratory mortalityRetrospective Cohortsputum conversionwatchful waiting
Share12Tweet7Share2ShareShareShare1

Related Posts

Women With Dysmenorrhea Show Limited Endometriosis Knowledge Despite Proactive Health Practices

Women With Dysmenorrhea Show Limited Endometriosis Knowledge Despite Proactive Health Practices

November 21, 2026
Macrophage CD38 Drives Placental Senescence by Depleting Cellular NAD+ Pools

Macrophage CD38 Drives Placental Senescence by Depleting Cellular NAD+ Pools

November 21, 2026

Forearm Melanoma Bypasses the Axilla to a Solitary Interval Lymph Node

November 21, 2026

Rare Sjögren’s Syndrome Case Presents With Complete Heart Block and Myocardial Injury

November 21, 2026

POPULAR NEWS

  • Targeting Lipid Remodeling Restores Cytotoxicity in Aged Natural Killer Cells

    Targeting Lipid Remodeling Restores Cytotoxicity in Aged Natural Killer Cells

    29 shares
    Share 12 Tweet 7
  • Periodic Plane-Wave Quantum Algorithms Successfully Calculate Molecular Energies on Trapped-Ion Hardware

    29 shares
    Share 12 Tweet 7
  • Furmonertinib Rechallenge Controlled Lung Adenocarcinoma Following Almonertinib-Induced Interstitial Lung Disease

    29 shares
    Share 12 Tweet 7
  • Surgeons Preserve Fertility While Removing Giant Ovarian Cyst Masked by Obesity

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Enhanced Linear Attention Model Improves Accuracy in Legal Judgment Prediction Tasks

Lightweight WDF-YOLO Detector Enhances Underwater Object Detection Accuracy Over Baseline Model

Combining Semi-Rigid Foam and Cement Boosts Clay Soil Bearing Capacity Substantially

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.